- Invenra and Xcellon Biologics have entered a strategic collaboration to advance bispecific and trispecific antibody–drug conjugates (ADCs) from discovery to preclinical and clinical development.
- The partnership combines Invenra’s B-Body® and T-Body™ antibody platforms with Xcellon’s bioconjugation, ADC development, and manufacturing expertise.
Invenra Inc. and Xcellon Biologics, a U.S.-based CDMO specializing in antibody–drug conjugates (ADCs) and complex biologics, have announced a strategic collaboration to accelerate the development of multispecific ADCs. The partnership aims to translate bispecific and trispecific ADC candidates from discovery into preclinical and clinical studies more efficiently.
Under the agreement, Invenra will utilise its proprietary B-Body® Bispecific and T-Body™ Trispecific platforms to generate novel multispecific antibody formats. Xcellon Biologics will provide integrated bioconjugation, ADC development, and manufacturing services to evaluate and advance these candidates.
The collaboration is designed to streamline ADC progression, leveraging Invenra’s rapid discovery platforms to reduce optimisation time and de-risk the development process. Bonnie Hammer, Executive VP R&D of Invenra, stated, “Our platforms eliminate lengthy optimisation, supporting a seamless path from initial discovery to clinical ADC candidates.”
Xcellon Biologics’ U.S.-based infrastructure will support advanced ADC programmes from concept through IND-enabling studies. Abhishake Chhibber, Board Member of Xcellon Biologics, commented, “Partnering with Invenra strengthens that mission by combining cutting-edge multispecific antibody discovery with Xcellon’s integrated bioconjugation and ADC development capabilities.”
